Active Biotech Interim Report January-March 2004


  • SAIK-MS project advancing further
  • TTS CD3 for lung cancer progressing according to plan
  • New collaboration with Avidex Ltd.
  • Phase I study for the SLE project planned to start during third quarter
  • Patient study for prostate-cancer project TASQ to commence during the autumn of 2004
  • Focus on clinical projects being implemented, negotiations in accordance with labour market legislation completed
  • Loss after net financial items SEK 42.5 M (loss: 60.4)
  • Loss per share for the period amounted to SEK 1.26 (loss: 4.72)
  • Loss after tax SEK 42.5 M (loss: 60.4)

pdfActive Biotech AB Interim Report Jan-Mar